GSK Deal, Fevertree Up, Seraphim Soars

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- GSK agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.
- Fever-Tree shares rise as much 8.2% to the highest in a month after the company said it was on track to meet expectations and extended its buyback program.
- Seraphim Space Investment Trust shares rise as much as 26%, their biggest jump in almost three years, after the fund said the fair value of Iceye, its largest holding, had doubled after a funding round. Shares of Molten Ventures, which also invests in Iceye, gain as much as 12%.

See omnystudio.com/listener for privacy information.